Point mutation in the exoplasmic domain of the erythropoietin receptor resulting in hormone-independent activation and tumorigenicity
- 1 December 1990
- journal article
- Published by Springer Science and Business Media LLC in Nature
- Vol. 348 (6302), 647-649
- https://doi.org/10.1038/348647a0
Abstract
The receptors for erythropoietin and other cytokines constitute a new superfamily. They have no tyrosine-kinase or other enzyme motif and their signal-transducing mechanism is unclear. Here we describe two classes of activating mutations in the erythropoietin receptor (EPOR). A single point mutation in the exoplasmic domain enables it to induce hormone-independent cell growth and tumorigenesis after expression in nontumorigenic, interleukin-3-dependent haematopoietic cells. A C-terminal truncation in the cytoplasmic domain of the EPOR renders the receptor hyperresponsive to erythropoietin, but is insufficient to induce hormone-independent growth or tumorigenicity. The activating point mutation retards intracellular transport and turnover of the receptor. These alterations in metabolism and tumorigenicity caused by the EPOR with activating point mutations are similar to those observed in erythropoietin-independent activation of the wild type EPOR by association with gp55, the Friend spleen focus-forming virus glycoprotein.Keywords
This publication has 20 references indexed in Scilit:
- Immune and hematopoietic cell regulation: cytokines and their receptorsCurrent Opinion in Cell Biology, 1990
- Expression cloning of a receptor for murine granulocyte colony-stimulating factorCell, 1990
- A restricted cytoplasmic region of IL-2 receptor β chain is essential for growth signal transduction but not for ligand binding and internalizationCell, 1989
- A novel family of growth factor receptors: A common binding domain in the growth hormone, prolactin, erythropoietin and IL-6 receptors, and the p75 IL-2 receptor β-chainBiochemical and Biophysical Research Communications, 1989
- Erythropoietin receptor and interleukin-2 receptor β chain: A new receptor familyCell, 1989
- Expression cloning of the murine erythropoietin receptorCell, 1989
- A point mutation in the extracellular domain of the human CSF-1 receptor (c-fms proto-oncogene product) activates its transforming potentialCell, 1988
- Activation of the feline c-fms proto-oncogene: Multiple alterations are required to generate a fully transformed phenotypeCell, 1988
- Transforming potential of the c-fms proto-oncogene (CSF-1 receptor)Nature, 1987
- Expression of a hemopoietic growth factor cDNA in a factor-dependent cell line results in autonomous growth and tumorigenicityCell, 1985